Lantheus Holding Stock Price, News & Analysis

Lantheus Holdings (NASDAQ: LNTH) announced FDA acceptance of a New Drug Application (NDA) for a new formulation of its F 18 PSMA imaging agent. The FDA has set a PDUFA date of March 6, 2026 for the application filed by Lantheus' affiliate, Aphelion.

The new formulation is designed to optimize manufacturing and increase batch size by approximately 50%, building on the success of PYLARIFY, Lantheus' market-leading PSMA PET imaging agent. PYLARIFY has demonstrated an 86% median true-positive rate in detecting recurrent prostate cancer. The enhanced formulation aims to maintain the same efficacy while improving patient access and operational efficiency through increased radioactive concentration.

Lantheus Holdings (NASDAQ: LNTH) has scheduled its second quarter 2025 earnings conference call and webcast for August 6, 2025, at 8:00 a.m. ET. During this event, the company will discuss its Q2 2025 financial results and provide a business update.

Participants can register for the event at investor.lantheus.com/news-events/calendar-of-events. Registration is recommended 15 minutes before the start time. A replay will be available approximately two hours after the webcast and will remain accessible for at least 30 days.

Lantheus Holdings (NASDAQ: LNTH) has completed its acquisition of Life Molecular Imaging Ltd., a subsidiary of Life Healthcare Group Holdings Ltd. The company has appointed Dr. Ludger Dinkelborg, former CEO of Life Molecular Imaging, as Head of Research and Development effective August 1, 2025.

Through this strategic acquisition, Lantheus gains Neuraceq®, a globally approved F-18 PET imaging agent for detecting beta-amyloid plaques in Alzheimer's disease evaluation. The deal strengthens Lantheus's position in Alzheimer's diagnostics with enhanced commercial infrastructure, R&D capabilities, and international presence.

Lantheus Holdings (NASDAQ: LNTH) announced upcoming presentations of new data for two oncology radiodiagnostic agents at the 2025 SNMMI Annual Meeting in New Orleans from June 21-24, 2025. The presentations include research on their FAP imaging agent [64Cu]LNTH-1363S and 18F-Piflufolastat PET/CT for prostate cancer detection. Key presentations feature optimization of production methods, clinical evaluation of 68Ga-LNTH-1363S in cancer patients, prostate cancer detection capabilities, and preclinical assessment for myocardial infarction imaging. The research showcases Lantheus's continued advancement in radiopharmaceutical development and diagnostic imaging technologies.

Lantheus Holdings (NASDAQ: LNTH), a leading radiopharmaceutical company, announced that CEO Brian Markison will present at the 2025 Truist Securities MedTech Conference on Tuesday, June 17 at 8:40 a.m. ET. The presentation will be accessible via live webcast through the Investors section of Lantheus's website at www.lantheus.com. A replay will remain available on the company's website for a minimum of 30 days after the live presentation.

Lantheus Holdings (NASDAQ: LNTH), a leading radiopharmaceutical company, announced that CEO Brian Markison will present at the Goldman Sachs 46th Annual Global Healthcare Conference 2025. The presentation is scheduled for Tuesday, June 10, at 2:40 p.m. ET. Investors and interested parties can access the live webcast through the Investors section of Lantheus's website at www.lantheus.com. A replay of the presentation will remain available on the company's website for a minimum of 30 days after the live event.

PharmaLogic Holdings Corp. has appointed Etienne Montagut as its new President and Chief Executive Officer, effective June 1, 2025. Montagut, who previously served as President, brings over 25 years of senior leadership experience in the pharmaceutical industry, with previous executive roles at Lantheus, GE HealthCare, and Ipsen. He succeeds Steve Chilinski, who retired after leading the company through 13 years of growth and will transition to Executive Chairman of the Board. The leadership change positions PharmaLogic, a leading radiopharmaceutical CDMO, to continue its expansion in novel diagnostics and therapies development.

Lantheus Holdings (NASDAQ: LNTH) reported Q1 2025 financial results with worldwide revenue of $372.8M, up 0.8% YoY. GAAP earnings per share decreased to $1.02 from $1.87, while adjusted EPS fell to $1.53 from $1.69. Key product performance included PYLARIFY sales of $257.7M (-0.5%) and DEFINITY sales of $79.2M (+3.5%). The company's cash position strengthened to $938.5M. Lantheus announced significant strategic moves: completing the Evergreen Theragnostics acquisition, expecting to close Life Molecular Imaging acquisition soon, and planning to divest its SPECT business. The company reported positive data for MK-6240 pivotal studies and plans an NDA filing in Q3 2025. However, the Phase 3 SPLASH study showed confounded results, leading to discontinued pursuit of the PNT2002 program. The company updated its FY2025 guidance, now projecting revenue of $1.550B-$1.585B and adjusted EPS of $6.60-$6.70, lower than previous estimates.

Lantheus Holdings (NASDAQ: LNTH) has announced a definitive agreement to sell its SPECT business to SHINE Technologies. The transaction includes the sale of diagnostic agents TechneLite®, NEUROLITE®, Xenon Xe-133 Gas, and Cardiolite®, along with related manufacturing facilities in North Billerica, Massachusetts, and Canadian operations. The deal allows Lantheus to focus on its innovative PET radiodiagnostics and microbubbles portfolio while advancing its radiopharmaceutical pipeline.

The transaction terms include an upfront cash payment, a note convertible into SHINE preferred stock, and potential earnout milestones. This strategic move follows Lantheus' recent agreements to acquire Life Molecular Imaging and Evergreen Theragnostics. The deal is expected to close by year-end, subject to customary conditions.